You are here

Zai Lab

AbbVie calls off PhI trial for I-Mab’s CD47 days after Zai Lab shelves its own program

Endpoints

Tue, 08/16/22 - 11:59 pm

clinical trials

Biopharma Companies Entering 2021 With New Collabs, Partnerships

BioSpace

Sat, 01/9/21 - 07:42 pm

Dewpoint Therapeutics

Nurix Therapeutics

Corporate and regulatory developments over the holidays

EP Vantage

Mon, 01/4/21 - 10:20 am

Bristol-Myers Squibb

Cullinan Oncology

Myovant Sciences

Osmotica Pharmaceuticals

Y-mAbs Therapeutics

United Therapeutics

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

BioCentury

Wed, 07/3/19 - 12:07 am

PD-1 inhibitors

With potential launches nearing, Zai taps investors for $200M

BioCentury

Fri, 05/3/19 - 10:45 pm

First Patient Dosed in Ph III Trial of Bemarituzumab for Advanced Gastric and Gastroesophageal Junction Cancers

CP Wire

Mon, 10/1/18 - 09:38 am

First Patient Dosed in Ph III Trial of Bemarituzumab for Advanced Gastric and Gastroesophageal Junction Cancers

Mon, 10/1/18 - 09:38 am

Zai Lab bombs Phase IIa trial in atopic dermatitis, junks the program to shift resources to the pipeline

Endpoints

Sat, 08/25/18 - 09:38 pm

clinical trials

Prepping a drug launch, Zai Lab poaches AstraZeneca’s top cancer drug sales exec in China

Endpoints

Tue, 06/5/18 - 12:06 pm

Unstoppable growth of Chinese biotechs attracts over $10bn funding

GoinPharma

Mon, 11/27/17 - 09:07 am